BioCorRx (OTC:BICX) announced this month that it won a two-year grant from the NIH’s National Institute on Drug Abuse to support the development of its sustained release naltrexone implant for the treatment of opioid use disorder. The grant includes $2.8 million for Feb. 1, 2019 to Jan. 31, 2020, followed by $2.8 million for the second […]
Proteus Digital Health announced earlier this month that Anthem‘s (NYSE:ANTM) executive chairman, Joseph Swedish, joined the company’s board of directors. Swedish served as Anthem’s president & chief executive from 2013 until he was appointed executive chairman in 2018. Get the full story at our sister site, Drug Delivery Business News.
BioCorRx (OTC:BICX) said today that it inked a confidentiality agreement with the National Institute on Drug Abuse, which will allow the group to share information and potentially work together on R&D and commercialization of BioCorRx’s therapies for opioid use disorder. The National Institutes of Health division has also agreed to participate as an observer at the […]
BioCorRx (OTC:BICX) said today that it partnered with the Virtual Reality Medical Center to conduct a study on the company’s long-lasting naltrexone implant. BioCorRx’s recovery program consists of a long-lasting implant that delivers an opioid antagonist, naltrexone, which reduces physical cravings for alcohol and opioids. The recovery service also has a counseling program specifically designed […]
BioCorRx (OTC:BICX) said today that the FDA has granted the anti-addiction developer a pre-investigational new drug meeting, scheduled for Sept. 19. The Anaheim, Calif.-based company said it is slated to review the development and marketing plan for BICX101, an injectable, sustained-release formulation of naltrexone as a therapy for opioid addiction and alcohol use disorders. Get […]
Anti-addiction developer BioCorRx said today it launched a research & development initiative as it seeks FDA approval for its naltrexone implant designed to treat opioid and alcohol addictions. If you have problem with addictions then read this blog. The implant slowly releases naltrexone, a non-addictive opioid antagonist that can reduce physical cravings and block some […]